Multiplicative interactions to enhance gabapentin to treat neuropathic pain

Department of Anesthesiology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA.
European Journal of Pharmacology (Impact Factor: 2.53). 10/2008; 598(1-3):21-6. DOI: 10.1016/j.ejphar.2008.09.004
Source: PubMed


We previously reported that gabapentin activates the bulbospinal-spinal noradrenergic-cholinergic pathway to produce analgesia in rats after nerve injury. Also, gabapentin interacts synergistically with a cholinesterase inhibitor donepezil to produce analgesia. Duloxetine, a serotonin/noradrenaline re-uptake inhibitor, has been used for the treatment of neuropathic pain and should amplify the noradrenergic mechanisms recruited by gabapentin. In the present study, we determined the interaction between duloxetine and gabapentin with and without donepezil when administered by the clinically preferred oral route in rats after spinal nerve ligation. The ED(50) value of gabapentin, donepezil, and duloxetine to reduce mechanical hypersensitivity after nerve injury was 45, 3.7, and 32 mg/kg, respectively. In the examination of two drug combinations, oral duloxetine with either gabapentin or donepezil were additive to reduce hypersensitivity. The combination of all three drugs yielded a synergistic interaction with an observed ED(50) at 1/4th the predicted dose of additivity, likely due to the gabapentin-donepezil interaction. This three drug combination did not affect motor coordination or show signs of sedation in the rotarod test. Analgesia by the combination of these three drugs was reversed by intrathecal injection either of the alpha(2)-adrenoceptor antagonist idazoxan or by the muscarinic receptor antagonist atropine. These results suggest that the combination of these drugs, which stimulate and augment the bulbospinal-spinal noradrenergic-cholinergic pathway, lowers the dose requirement for each drug to reduce hypersensitivity after nerve injury without sedative effects. The current study provides the rationale for clinical study of the combination of gabapentin, donepezil and duloxetine to treat neuropathic pain.

Full-text preview

Available from:
  • Source
    • "We could gather evidence that Gabapentin and Pregabalin inhibit the release of excitatory neurotransmitters by blocking the calcium channel and could be more useful in lancinating pain and allodynia.[4041] We decided to start Mrs. Kamble on Cap Gabapentin 300 mg along with Amitriptyline 25 mg at night based on reports[4243] that combination of calcium channel alfa-2-delta blockers and antidepressants was safe and effective in controlling the neuropathic pain. Patient could not afford Pregabalin and there was no evidence to suggest that it was superior to Gabapentin. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuropathic pain is a distressing symptom for the patient and a difficult symptom for the physician to treat. There is lack of evidence-based clinical guidelines for the management of malignant neuropathic pain. The case reflection is a personal account of what has been learnt from a critical incident in a particular patient in the management of neuropathic pain. Psychological issues are known to increase pain percetion and affect the quality of life. The case reflection explores problem areas, defines lacunae in knowledge, and demonstrates active learning of the management of neuropathic pain through reflective practice.
    Full-text · Article · May 2011 · Indian Journal of Palliative Care
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Agent-based systems add unique aspects to assessment activity and require the use of traditional tools and techniques in new or unconventional ways and the development of new, domain-customized tools. Agent-based system assessments must address the same issues as those of traditional systems: unsafe programming practices, such as failure to validate inputs or use of insecure libraries. Assessments of agent-based systems should also include "system-of-systems" concepts. Complex systems interact with and rely on other systems that may exist independently. A system-of-systems assessment identifies systems and their behaviors and considers ways that those behaviors can interact to harm the complex system. Attacks are then developed to cause the desired behavior. Agent-based systems are aware of and respond to their environment through adaptation and evolution. They require assessment through concepts normally reserved for humans. Just as adversaries cause humans to react in ways advantageous to the attacker, agent-based system assessors must cause agents to react. These assessments require "social engineering" of the agents just as simpler systems may require "social engineering" of users and administrators. This paper discusses the application of existing and new tools and techniques to agent system assessments including descriptions of actual and theoretical attacks.
    Full-text · Conference Paper · Sep 2004
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The present study investigated the effects of systemic administration of dexmedetomidine, a selective alpha2 adrenergic receptor (alpha2AR) agonist, and gabapentin either alone or in combination on thermal hyperalgesia evoked by ankle joint inflammation. Monoarthritis of rat ankle joint was induced by an intra-articular injection of Complete Freund's Adjuvant (CFA). The paw withdrawal latency (PWL) from a thermal stimulus was measured in awake rats. Intraperitoneal (i.p.) injection of dexmedetomidine (2.5, 5, 10 and 20 microg/kg) or gabapentin (25, 50, 100 and 200 mg/kg) significantly and dose-dependently increased the PWL of the hindpaw ipsilateral to CFA-injected joint. The PWLs of the non-injected and normal saline (NS)-injected hindpaws were not significantly affected by the two agents at the most doses tested except the highest dose of dexmedetomidine (20 microg/kg). Although low dose of dexmedetomidine (2.5 microg/kg) or gabapentin (25 mg/kg) alone did not affect or lightly increased PWLs of the hindpaw ipsilateral to CFA-injected joint, a combination of dexmedetomidine and gabapentin (2.5 microg/kg+25 mg/kg, or 5 microg/kg+50 mg/kg) significantly reversed CFA-induced thermal hyperalgesia for 60 min without sedation/motor impairment. These results provide the first identification that co-application of dexmedetomidine and gabapentin may synergistically antagonize inflammatory pain, and this might prove to be beneficial in the treatment of arthritic pain.
    Full-text · Article · Feb 2009 · Brain research
Show more